Dear investors and female investors,
held this afternoon at 14.30 clock, the German biotechnology company MediGene AG a conference call in English this morning to explain the reported figures . On that I have attended as a representative of the Sharewise GmbH and would therefore like to quote here the two most interesting statements of MediGene management. The conference call was attended on the part of MediGene AG following persons: Dr. Matthias Frank, CEO of MediGene AG, Dr. Thomas Klaue, CFO of MediGene AG and Dr. Axel Mescheder, CDO of MediGene AG.
The conference call began with CEO Dr. Frank Matt and CFO Thomas presented the claw again this morning already reported financial results. Following this there was the possibility of the management of MediGene AG ask questions about these figures or to continue building the company into its respective drug development.
were asked about 10 questions total, 8 to make of it EndoTAG-1, which also proves the analyst of this drug for the primary drug of MediGene AG . In summary, resulted primarily from CEO Dr. Matthias Frank, that would currently work two teams EndoTAG-1, once a "research team" that the further development of the drug candidate advancing, and even a "marketing team" that negotiations with potential partners. Further development of EndoTAG-1 is not affected by the negotiations for a partnership. The potential partner, CEO Dr. Matthias said quite clearly in the majority, were constantly informed about the further development work. Currently examining the management of the individual offers, and would soon decide on an offer, namely that which the MediGene AG and its shareholders offer the most advantages. MediGene AG would definitely present at the beginning of a partnership, a one-time payment and milestone payments later date, and End Success set to continue its sales and profits, says CEO Dr. Frank Matthias. Although it was intended with respect to the time frame when the EndoTAG-1 Deal come, even more information than today announced tomorrow with the figures (even in 2009 "), from the evidence given by CEO Dr. Matthias see what I meant, however, can see that this deal would come very soon. I therefore limit the period in relation to a EndoTAG-1 Deal a significantly narrower than the company itself and expect that by the end of September. Let's see if I'm right ...
In addition, there was a second information that was already reported even tomorrow, but probably was a little lost / is. And although has received the MediGene AG against the issuance of 20,000 Shares to be in the amount of 100,000 € from YA Global Investments. Background had been here that wanted to test MediGene AG whether one could rely on the YA Global Investments. This may be a little strange, but CFO Dr. Thomas Klaue in the explanation of this situation seemed very confident. Because of this, and as the MediGene AG actually still has enough cash reserves, believed and I think, and probably the participating analysts this, but curious, explanation.
Otherwise there was not much new. Much more confirmed the MediGene Management only repeat those already in the message published this morning, statements made regarding the two drugs already on the market Eligard and Veregen. Wherein said actually looked like only a question of all these imported drugs already on the market ...
I think this was a short, but above all for MediGene shareholders very interesting summary of the conference call this afternoon. If you still have any questions, please do not hesitate and make that easy here as a comment. If possible, I try to correct them as quickly as possible to answer ...
your Sascha
0 comments:
Post a Comment